Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12964-022-00868-6.

Title:
Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability | Cell Communication and Signaling
Description:
Background Transcription factor c-Myc plays a critical role in various physiological and pathological events. c-Myc gene rearrangement is closely associated with multiple myeloma (MM) progression and drug resistance. Thereby, targeting c-Myc is expected to be a useful therapeutic strategy for hematological disease, especially in MM. Methods Molecular docking-based virtual screening and dual-luciferase reporter gene assay were used to identify novel c-Myc inhibitors. Cell viability and flow cytometry were performed for evaluating myeloma cytotoxicity. Western blot, immunofluorescence, immunoprecipitation, GST pull down and Electrophoretic Mobility Shift Assay were performed for protein expression and interaction between c-Myc and Max. c-Myc downstream targets were measured by Q-PCR and Chromatin immunoprecipitation methods. Animal experiments were used to detect myeloma xenograft and infiltration in vivo. Results We successfully identified a novel c-Myc inhibitor D347-2761, which hindered the formation of c-Myc/Max heterodimer and disturbed c-Myc protein stability simultaneously. Compound D347-2761 dose-and time-dependently inhibited myeloma cell proliferation and induced apoptosis. Dual knockout Bak/Bax partially restored D347-2761-mediated cell death. Additionally, compound D347-2761 could, in combination with bortezomib (BTZ), enhance MM cell DNA damage and overcome BTZ drug resistance. Our in vivo studies also showed that compound D347-2761 repressed myeloma growth and distal infiltration by downregulating c-Myc expression. Mechanistically, novel dual-targeting c-Myc inhibitor D347-2761 promoted c-Myc protein degradation via stimulating c-Myc Thr58 phosphorylation levels, which ultimately led to transcriptional repression of CDK4 promoter activity. Conclusions We identified a novel dual-targeting c-Myc small molecular inhibitor D347-2761. And this study may provide a solid foundation for developing a novel therapeutic agent targeting c-Myc. Video Abstract
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Science
  • Education
  • Health & Fitness

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

We can't figure out the monetization strategy.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {๐Ÿ”}

cmyc, cells, cell, article, myeloma, compound, fig, rpmi, google, scholar, assay, expression, protein, cas, analysis, treated, inhibitor, btz, apoptosis, cmycmax, dna, additional, group, molecular, treatment, file, stability, western, ncih, multiple, blot, damage, cdk, binding, dose, gene, drug, max, studies, showed, transcriptional, tumor, phosphorylation, target, china, control, figure, screening, results, degradation,

Topics {โœ’๏ธ}

2ย ฮผg p3flag-cmv-9-c-myc plasmids annexin v-apc/7-aad assay p3flag-cmv-9-myc plasmid pan-caspase inhibitor z-vad-fmk block c-myc/max heterodimerization targeting c-myc/max interaction blocking c-myc/max heterodimerization flag-tagged c-myc plasmids c-myc/max heterodimers bound c-myc response elements c-myc/max heterodimer significantly c-myc/max interaction domain c-myc unstable domain destroy c-myc/max interaction c-myc/max complex binding c-myc/max mutants obtained f-box protein fbw7 c-myc inhibitory activity proteasome-mediated protein degradation c-myc protein half-life c-myc/max complex interface dna double-strand breaks potential c-myc inhibitor c-myc transcriptional target disturb c-myc stability c-myc-mediated oncogenesis purchased commercial gst-c-myc c-myc thr58 promoted exogenous flag-c-myc c-myc inhibitor d347-2761 c-myc protein stability c-myc/max heterodimerization c-myc gene rearrangement c-myc protein instability c-myc/max complex c-myc binding sites e-box motif proto-oncogenic transcription factors c-mycโ€“mediated physiological time-dependently inhibited rpmi-8226 targeting c-myc myc-max oncoprotein complex transcription factor c-myc c-myc promoter activity structure-based virtual screening c-myc downstream targets c-myc/max heterodimer phosphorylate c-myc thr58 pim kinase-dependent inhibition p-c-myc ser62

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
         description:Transcription factor c-Myc plays a critical role in various physiological and pathological events. c-Myc gene rearrangement is closely associated with multiple myeloma (MM) progression and drug resistance. Thereby, targeting c-Myc is expected to be a useful therapeutic strategy for hematological disease, especially in MM. Molecular docking-based virtual screening and dual-luciferase reporter gene assay were used to identify novel c-Myc inhibitors. Cell viability and flow cytometry were performed for evaluating myeloma cytotoxicity. Western blot, immunofluorescence, immunoprecipitation, GST pull down and Electrophoretic Mobility Shift Assay were performed for protein expression and interaction between c-Myc and Max. c-Myc downstream targets were measured by Q-PCR and Chromatin immunoprecipitation methods. Animal experiments were used to detect myeloma xenograft and infiltration in vivo. We successfully identified a novel c-Myc inhibitor D347-2761, which hindered the formation of c-Myc/Max heterodimer and disturbed c-Myc protein stability simultaneously. Compound D347-2761 dose-and time-dependently inhibited myeloma cell proliferation and induced apoptosis. Dual knockout Bak/Bax partially restored D347-2761-mediated cell death. Additionally, compound D347-2761 could, in combination with bortezomib (BTZ), enhance MM cell DNA damage and overcome BTZ drug resistance. Our in vivo studies also showed that compound D347-2761 repressed myeloma growth and distal infiltration by downregulating c-Myc expression. Mechanistically, novel dual-targeting c-Myc inhibitor D347-2761 promoted c-Myc protein degradation via stimulating c-Myc Thr58 phosphorylation levels, which ultimately led to transcriptional repression of CDK4 promoter activity. We identified a novel dual-targeting c-Myc small molecular inhibitor D347-2761. And this study may provide a solid foundation for developing a novel therapeutic agent targeting c-Myc.
         datePublished:2022-05-26T00:00:00Z
         dateModified:2022-05-26T00:00:00Z
         pageStart:1
         pageEnd:16
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12964-022-00868-6
         keywords:
            c-Myc inhibitor
            Multiple myeloma
            DNA damage
            Drug resistance
            Apoptosis
            Cell Biology
            Protein-Ligand Interactions
            Receptors
            Cytokines and Growth Factors
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig8_HTML.png
         isPartOf:
            name:Cell Communication and Signaling
            issn:
               1478-811X
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ruosi Yao
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
                     name:The Affiliated Hospital of Xuzhou Medical University
                     address:
                        name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Xuzhou Ruihu Health Management and Consulting Co., Ltd
                     address:
                        name:Xuzhou Ruihu Health Management and Consulting Co., Ltd, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Menghui Zhang
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jian Zhou
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Linlin Liu
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:College of Medical Imaging, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yan Zhang
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jian Gao
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kailin Xu
               url:http://orcid.org/0000-0003-1375-1084
               affiliation:
                     name:Xuzhou Medical University
                     address:
                        name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
                     name:The Affiliated Hospital of Xuzhou Medical University
                     address:
                        name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
      description:Transcription factor c-Myc plays a critical role in various physiological and pathological events. c-Myc gene rearrangement is closely associated with multiple myeloma (MM) progression and drug resistance. Thereby, targeting c-Myc is expected to be a useful therapeutic strategy for hematological disease, especially in MM. Molecular docking-based virtual screening and dual-luciferase reporter gene assay were used to identify novel c-Myc inhibitors. Cell viability and flow cytometry were performed for evaluating myeloma cytotoxicity. Western blot, immunofluorescence, immunoprecipitation, GST pull down and Electrophoretic Mobility Shift Assay were performed for protein expression and interaction between c-Myc and Max. c-Myc downstream targets were measured by Q-PCR and Chromatin immunoprecipitation methods. Animal experiments were used to detect myeloma xenograft and infiltration in vivo. We successfully identified a novel c-Myc inhibitor D347-2761, which hindered the formation of c-Myc/Max heterodimer and disturbed c-Myc protein stability simultaneously. Compound D347-2761 dose-and time-dependently inhibited myeloma cell proliferation and induced apoptosis. Dual knockout Bak/Bax partially restored D347-2761-mediated cell death. Additionally, compound D347-2761 could, in combination with bortezomib (BTZ), enhance MM cell DNA damage and overcome BTZ drug resistance. Our in vivo studies also showed that compound D347-2761 repressed myeloma growth and distal infiltration by downregulating c-Myc expression. Mechanistically, novel dual-targeting c-Myc inhibitor D347-2761 promoted c-Myc protein degradation via stimulating c-Myc Thr58 phosphorylation levels, which ultimately led to transcriptional repression of CDK4 promoter activity. We identified a novel dual-targeting c-Myc small molecular inhibitor D347-2761. And this study may provide a solid foundation for developing a novel therapeutic agent targeting c-Myc.
      datePublished:2022-05-26T00:00:00Z
      dateModified:2022-05-26T00:00:00Z
      pageStart:1
      pageEnd:16
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12964-022-00868-6
      keywords:
         c-Myc inhibitor
         Multiple myeloma
         DNA damage
         Drug resistance
         Apoptosis
         Cell Biology
         Protein-Ligand Interactions
         Receptors
         Cytokines and Growth Factors
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-022-00868-6/MediaObjects/12964_2022_868_Fig8_HTML.png
      isPartOf:
         name:Cell Communication and Signaling
         issn:
            1478-811X
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ruosi Yao
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
                  name:The Affiliated Hospital of Xuzhou Medical University
                  address:
                     name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Xuzhou Ruihu Health Management and Consulting Co., Ltd
                  address:
                     name:Xuzhou Ruihu Health Management and Consulting Co., Ltd, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Menghui Zhang
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jian Zhou
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Linlin Liu
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:College of Medical Imaging, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yan Zhang
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jian Gao
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kailin Xu
            url:http://orcid.org/0000-0003-1375-1084
            affiliation:
                  name:Xuzhou Medical University
                  address:
                     name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
                  name:The Affiliated Hospital of Xuzhou Medical University
                  address:
                     name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cell Communication and Signaling
      issn:
         1478-811X
      volumeNumber:20
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Xuzhou Medical University
      address:
         name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:The Affiliated Hospital of Xuzhou Medical University
      address:
         name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Ruihu Health Management and Consulting Co., Ltd
      address:
         name:Xuzhou Ruihu Health Management and Consulting Co., Ltd, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Medical University
      address:
         name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Medical University
      address:
         name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Medical University
      address:
         name:College of Medical Imaging, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Medical University
      address:
         name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Medical University
      address:
         name:Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:Xuzhou Medical University
      address:
         name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
      name:The Affiliated Hospital of Xuzhou Medical University
      address:
         name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ruosi Yao
      affiliation:
            name:Xuzhou Medical University
            address:
               name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
            name:The Affiliated Hospital of Xuzhou Medical University
            address:
               name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
            name:Xuzhou Ruihu Health Management and Consulting Co., Ltd
            address:
               name:Xuzhou Ruihu Health Management and Consulting Co., Ltd, Xuzhou, China
               type:PostalAddress
            type:Organization
      name:Menghui Zhang
      affiliation:
            name:Xuzhou Medical University
            address:
               name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
      name:Jian Zhou
      affiliation:
            name:Xuzhou Medical University
            address:
               name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
      name:Linlin Liu
      affiliation:
            name:Xuzhou Medical University
            address:
               name:College of Medical Imaging, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
      name:Yan Zhang
      affiliation:
            name:Xuzhou Medical University
            address:
               name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
      name:Jian Gao
      affiliation:
            name:Xuzhou Medical University
            address:
               name:Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kailin Xu
      url:http://orcid.org/0000-0003-1375-1084
      affiliation:
            name:Xuzhou Medical University
            address:
               name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
            name:The Affiliated Hospital of Xuzhou Medical University
            address:
               name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
      name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
      name:Xuzhou Ruihu Health Management and Consulting Co., Ltd, Xuzhou, China
      name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
      name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
      name:College of Medical Imaging, Xuzhou Medical University, Xuzhou, China
      name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
      name:Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
      name:Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China
      name:Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

External Links {๐Ÿ”—}(128)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js
  • Video.js

CDN Services {๐Ÿ“ฆ}

  • Crossref
  • Net/play">

Video Abstract

Similar content being viewed by others

5.92s.